Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION primary analysis.

被引：2

作者：

Poveda, Andres

Lheureux, Stephanie

Colombo, Nicoletta

Cibula, David

Lindemann, Kristina

Weberpals, Johanne I.

Bjurberg, Maria

Oaknin, Ana

Sikorska, Magdalena

Gonzalez Martin, Antonio

Madry, Radoslaw

Jesus Rubio, Maria

Ledermann, Jonathan A.

Davidson, Richard

Blakeley, Christopher

Bennett, James

Brown, Jessica

Skof, Erik

机构：

[1] Initia Oncol, Valencia, Spain

[2] Princess Margaret Hosp, Dept Med Oncol, Toronto, ON, Canada

[3] IEO Ist Europeo Oncol, Milan, Italy

[4] Charles Univ Hosp, Fac Med 1, Prague, Czech Republic

[5] Oslo Univ Hosp, Oslo, Norway

[6] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada

[7] Lund Univ, Skane Univ Hosp, Lund, Sweden

[8] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Gynaecol Canc Programme, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain

[9] Olsztyn Prov Specialist Hosp, Olsztyn, Poland

[10] Clin Univ Navarra, Madrid, Spain

[11] Lords Med Univ Karol Marcinkowski, Clin Hosp Transfigurat, Poznan, Poland

[12] Hosp Univ Reina Sofia, Dept Med Oncol, Cordoba, Spain

[13] UCL, UCL Canc Inst, London, England

[14] UCL Hosp, London, England

[15] AstraZeneca, Cambridge, England

[16] Inst Oncol Ljubljana, Ljubljana, Slovenia

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.5545

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5545

引用

页数：4

共 50 条

[21] Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china
Shu, Yamin
Liu, Yanxin
He, Xucheng
Ding, Yufeng
Zhang, Qilin
FRONTIERS IN PHARMACOLOGY, 2022, 13
[22] SABRINA study: A phase II study of senaparib monotherapy for patients (pts) with BRCA1/2 mutated recurrent platinum-sensitive ovarian cancer (PSOC)
Wu, X.
Liu, J.
Wang, L.
Lin, Z.
Wang, J.
Wang, C.
Kong, B.
Liang, Z.
Cheng, Y.
Wen, H.
Lou, G.
Huang, Y.
Wang, K.
An, R.
Zhu, J.
Zhou, H.
Yue, Y.
ANNALS OF ONCOLOGY, 2023, 34 : S521 - S521
[23] Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): Phase III SOLO2 trial
Ledermann, Jonathan A.
Lortholary, Alain
Penson, Richard T.
Gibbs, Emma
Provencher, Diane M.
Bruchim, Ilan
Huzarski, Tomas
Barretina-Ginesta, Maria Pilar
Sabbatini, Roberto
Mileshkin, Linda R.
Colombo, Nicoletta
Park-Simon, Tjoung-Won
Matsumoto, Koji
Sonke, Gabe S.
Mikheeva, Olga N.
Kim, Jae-Weon
Girotto, Gustavo Colagiovanni
Denys, Hannelore
Lowe, Elizabeth S.
Pujade-Lauraine, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[24] Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer
Mehra, Tarun
Lupatsch, Judith E.
Kossler, Thibaud
Dedes, Konstantin
Siebenhuner, Alexander Reinhard
von Moos, Roger
Wicki, Andreas
Schwenkglenks, Matthias E.
PLOS ONE, 2024, 19 (04):
[25] EXPLORING THE IMPACT OF RADIOGRAPHIC PROGRESSIVE DISEASE AND FIRST SUBSEQUENT THERAPY ON HEALTH STATE UTILITY VALUES IN GERMLINE-BRCA-MUTATED (GBRCAM) PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER (PSROC) PATIENTS ON OLAPARIB TABLETS AS MAINTENANCE MONOTHERAPY
Sackeyfio, A.
Santi, I
Friedlander, M.
VALUE IN HEALTH, 2018, 21 : S73 - S73
[26] First real life data on Olaparib in BRCA1/2 mutated Platinum-Sensitive Relapsed (PSR) Epithelial Ovarian Cancer (EOC) in France: Analysis of 52 patients (pts) enrolled in the French Temporary Authorization for Use (ATU)
Rouge, T. De La Motte
Pautier, P.
Alexandre, J.
Ray-Coquard, I.
Cottu, P.
Rodrigues, M.
Follana, P.
Floquet, A.
Lortholary, A.
Heudel, P. E.
Combe, P.
Joly, F.
Suau, D.
Maribas, D.
Licour, M.
De La Porte, I.
Varoqueaux, N.
Pujade-Lauraine, E.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S548 - S549
[27] Olaparib treatment in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Phase II LIGHT study.
Cadoo, Karen Anne
Simpkins, Fiona
Mathews, Cara Amanda
Kabil, Nashwa
Bennett, James
Aghajanian, Carol
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[28] POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline BRCA1/2 mutation (gBRCAm).
Golan, Talia
Oh, Do-Youn
Reni, Michele
Macarulla, Teresa Mercade
Tortora, Giampaolo
Hall, Michael J.
Reinacher-Schick, Anke C.
Borg, Christophe
Hochhauser, Daniel
Walter, Thomas
Hochster, Howard S.
Baker, Nigel
Locker, Gershon Y.
Kindler, Hedy L.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[29] Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
Penson, Richard T.
Villalobos Valencia, Ricardo
Cibula, David
Colombo, Nicoletta
Leath, Charles A., III
Bidzinski, Mariusz
Kim, Jae-Weon
Nam, Joo Hyun
Madry, Radoslaw
Hernandez, Carlos
Mora, Paulo A. R.
Ryu, Sang Young
Milenkova, Tsveta
Lowe, Elizabeth S.
Barker, Laura
Scambia, Giovanni
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (11) : 1164 - +
[30] COMPARATIVE EFFICACY AND SAFETY OF OLAPARIB 400 MG CAPSULES BID AND NIRAPARIB 300 MG TABLETS QD AS MAINTENANCE TREATMENT AFTER RESPONSE TO CHEMOTHERAPY IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED NON-GERMLINE BRCA-MUTATED OVARIAN CANCER (PSROC)
Sackeyfio, A.
Gill, J.
Hettle, R.
Siddiqui, K.
Friedlander, M.
Ledermann, J. A.
VALUE IN HEALTH, 2017, 20 (09) : A412 - A412

← 1 2 3 4 5 →